Clinical Trial Detail

NCT ID NCT02088684
Title Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Buparlisib + Fulvestrant + Ribociclib

Fulvestrant + Ribociclib

Alpelisib + Fulvestrant + Ribociclib

Age Groups: adult

Additional content available in CKB BOOST